Kisspeptin-10: Mechanism of Action in Published Studies

When people search "Kisspeptin-10 mechanism of action," they're asking what published research has actually examined at the receptor and physiological level. Here's what the literature describes — framed, as it must be, as receptor pharmacology and controlled human-dosing observations rather than claims about what the peptide does for a person.

GPR54/KISS1R signaling and the reproductive axis

Kisspeptin-10 corresponds to the shared C-terminal decapeptide sequence found in all bioactive fragments derived from the human KISS1 gene, including the longer 54-, 14-, and 13-amino-acid forms. Researchers isolating this peptide family from human placental tissue in 2001 reported that it bound with low-nanomolar affinity to the previously orphan receptor GPR54 (now designated KISS1R), triggering calcium mobilization and other downstream signaling in receptor-expressing cells [1]. Two years later, human genetics research reported that inactivating mutations in GPR54 were associated with idiopathic hypogonadotropic hypogonadism — a failure to enter puberty — placing this receptor system, and its kisspeptin ligands, upstream of GnRH neuron activity and the hypothalamic-pituitary-gonadal (HPG) axis [2].

Stimulating LH pulsatility in men

The first-in-human pharmacology study of Kisspeptin-10 specifically tested intravenous bolus doses (0.01–3.0 µg/kg) and continuous infusions in healthy men. A lower-dose continuous infusion (1.5 µg/kg·h over 9 hours) was reported to increase LH pulse frequency from approximately 0.7 to 1.0 pulses per hour, with the proportion of LH released as pulsatile secretion rising from roughly 41% to 70%. A separate, higher-dose infusion (4 µg/kg·h) sustained elevated LH for over 22 hours without the researchers observing tachyphylaxis in that timeframe, though it obscured individual pulse detection [3].

Hypogonadism context in type 2 diabetes

A related study extended this line of research beyond healthy volunteers, administering Kisspeptin-10 to men with type 2 diabetes and mild biochemical hypogonadism. That study reported increases in serum testosterone and LH secretion in this population, providing an early look at the peptide's studied activity in a population with impaired baseline gonadotropin signaling [4].

Cycle-dependent gonadotropin response (kisspeptin-54)

Because Kisspeptin-10 and the longer kisspeptin-54 fragment share the same bioactive C-terminal sequence and receptor target, research using kisspeptin-54 is directly relevant to understanding the pathway. Subcutaneous kisspeptin-54 was reported to increase plasma LH in women at every phase of the menstrual cycle tested, with the largest response — a mean increase of roughly 20.6 IU/L — during the preovulatory phase, and a much smaller response during the follicular phase, indicating that the pathway's studied sensitivity is not constant but varies with the underlying hormonal (largely estrogen) milieu [5].

How to read this

Each of these findings comes from controlled receptor-binding studies, human genetics research, or dosing studies in healthy or specific patient populations designed to characterize pharmacology and hormone secretion, not a therapeutic outcome. Chronic or repeated kisspeptin-54 dosing has also been reported to produce tachyphylaxis in some populations, which is a meaningful part of the mechanism picture. The value of this mechanism literature is that it tells researchers which receptor and hormonal pathways to study further, not what results to expect in a person.